Analysis of a limited number of patient samples revealed positivity for CD1c in 51% and CD1b in 54% of AML patients (n = 33), 71% of B-ALL samples expressed CD1c (n = 7), and 75% of pediatric T-ALL samples expressed CD1a and CD1b (n = 8) (64). This evidence concerns the gene CD1A and acute lymphoblastic leukemia.